Abstract
The traditionally auspicious ‘Big Pharma’ business model in the pharmaceutical industry is rapidly evolving. Large pharmaceutical companies are re-configuring their business models to achieve operational efficiency. The preferred option appears to be out-sourcing science-related R&D as opposed to conducting the research in-house. This has marked the ‘birth’ of born-global bio-tech firms which operate as contract research organisations. The firms are owner-managed by entrepreneurial scientists who generate social capital in the form of scientific knowledge and technical know-how by participating in multifarious global R&D networks. In that sense, this empirical study utilises multiple cases of born-global bio-tech firms sampled from the East Midlands in the UK to investigate how various mechanisms in their knowledge supply-chain (global networks), including complex business and social relationships, shape their social capital generating strategies. By doing so, the study contributes to the concept of dynamic capabilities and networking. The study is also invaluable to a number of stakeholders including: large and small firms, other researchers, and policy makers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Entrepreneurship and Small Business
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
